Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2026
Business Focus: The Company develops proprietary Heart3D Fusion Imaging software for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Intellectual Property Expansion: On April 28, 2026, the Company announced the allowance of a Japanese Patent titled "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."
- Impact: This patent provides additional intellectual property protection for the Company's Heart3D software.
- Application: The technology supports the CardiAMP Cell Therapy procedures.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the strategic value of the new patent in securing the Company's proprietary imaging technology.
Guidance and Risks: The filing text does not provide updated financial guidance, specific risk factors, or details on contingencies beyond the general context of intellectual property protection.
Investor Verification Checklist
- Verify the scope and enforceability of the newly allowed Japanese Patent regarding "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."
- Review the attached press release (Exhibit 99.1) for further details on the patent's commercial implications.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial performance data, as this 8-K contains no financial metrics.
- Confirm the status of the CardiAMP Cell Therapy procedures in relation to the new patent protection.